Source: Eur Respir Rev 2011; 20: 195-200
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Albera C.. Challenges in idiopathic pulmonary fibrosis trials: the point on end-points. Eur Respir Rev 2011; 20: 195-200

Member's Comments

No comment yet.

Related content which might interest you: The six minute walking test: Clinical predictors of survival in idiopathic pulmonary fibrosis Source: Annual Congress 2013 –The latest insights in exercise testing and physical inactivity Year: 2013 The timed walk test as a measure of severity and survival in idiopathic pulmonary fibrosis Source: Eur Respir J 2005; 25: 96-103 Year: 2005 A progression-free end-point for idiopathic pulmonary fibrosis trials: lessons from cancer Source: Eur Respir J 2013; 41: 262-269 Year: 2013 Effect of continued pirfenidone treatment following a ≥ 15% decline in 6-minute walk distance (6MWD) in patients with idiopathic pulmonary fibrosis (IPF): Pooled analysis from 3 pivotal studies Source: International Congress 2016 – New and old therapies for chronic lung diseases Year: 2016 Correlation of composite physiologic index with 6-minute walk test variables in patients with idiopathic interstitial pneumonias Source: International Congress 2016 – Clinical exercise physiology in health and disease Year: 2016 Changing the idiopathic pulmonary fibrosis treatment approach and improving patient outcomes Source: Eur Respir Rev 2012; 21: 161-167 Year: 2012 The effect of pulmonary rehabilitation on exercise tolerance pulmonary function dyspnea and quality of life in patients with idiopathic pulmonary fibrosis Source: Annual Congress 2013 –The best posters in pulmonary rehabilitation Year: 2013 Clinical predictors of pulmonary hypertension in sarcoidosis Source: Eur Respir J 2008; 32: 296-302 Year: 2008 Sex differences in physiological progression of idiopathic pulmonary fibrosis Source: Eur Respir J 2008; 31: 1183-1188 Year: 2008 Spirometric evaluation of idiopathic pulmonary fibrosis (IPF): forced or slow vital capacity? Source: International Congress 2019 – Biomarkers of idiopathic interstitial pneumonia Year: 2019 Clinical significance of falling oxygen saturation per walking distance (ΔSaO2/6MWD) during six minute walk test (6MWT) in idiopathic pulmonary fibrosis (IPF) Source: International Congress 2015 – IPF: clinical aspects Year: 2015 Pulmonary hypertension in idiopathic pulmonary fibrosis: correlation to pulmonary function and exercise parameters Source: Eur Respir J 2007; 30: Suppl. 51, 607s Year: 2007 Generalisability of recent clinical trials in idiopathic pulmonary fibrosis to everyday clinical practice Source: International Congress 2015 – Treatment of IPF Year: 2015 Differences in FVC decline by extent of emphysema in patients with combined pulmonary fibrosis and emphysema (CPFE) syndrome Source: International Congress 2015 – New frontiers in the management of interstitial and orphan lung diseases Year: 2015 Initial clinical experience with nintedanib for treatment of idiopathic pulmonary fibrosis (IPF): About 20 cases Source: International Congress 2015 – IPF: from bench to bedside Year: 2015 Efficacy of pirfenidone in idiopathic pulmonary fibrosis: A single center experience Source: International Congress 2016 – IPF: from pathogenesis to treatment II Year: 2016 Pulmonary rehabilitation in idiopathic pulmonary fibrosis: Predictors of adherence and exercise improvement Source: Annual Congress 2013 –The best posters in pulmonary rehabilitation Year: 2013 Pulmonary rehabilitation in patients with idiopathic pulmonary fibrosis: Comparison with COPD Source: Annual Congress 2013 –Exercise, physiotherapy techniques and assessment in different chronic conditions Year: 2013 A simple assessment of dyspnoea as a prognostic indicator in idiopathic pulmonary fibrosis Source: Eur Respir J 2010; 36: 1067-1072 Year: 2010